← Back to Search

Phase III (interview) for Blood Cancers

N/A

Recruiting

Led By Electra D Paskett, PhD

Research Sponsored by Ohio State University Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 24 months

Awards & highlights

Study Summary

"This trial is testing a project called CUSP2CT at The Ohio State University to see if it can increase the number of racial and ethnic minorities enrolling in clinical trials for cancer prevention and treatment

Who is the study for?

This trial is for racial and ethnic minority groups who are underrepresented in clinical trials, particularly those related to blood cancers, cancer in general, and tumors. The goal is to increase their participation in these important studies.Check my eligibility

What is being tested?

The CUSP2CT project at Ohio State University is being tested for its effectiveness in increasing referrals and enrollments of underrepresented minorities into cancer-related clinical trials through interviews, surveys, discussions, educational activities, and improving the accrual process.See study design

What are the potential side effects?

Since this trial involves non-medical interventions like interviews and education rather than drugs or medical procedures, there are no typical side effects associated with medications. Participants may experience discomfort from discussing personal health matters.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

CT accrual and retention due to patient navigation (short-term outcomes)

Change in accrual of minorities to CTs (short-term outcomes)

Change in referral to clinical trials (CTs) (short-term outcomes)

+2 more

Secondary outcome measures

Probability of trial enrollment and retention

Trial Design

3Treatment groups

Experimental Treatment

Group I: Phase III (interview)Experimental Treatment1 Intervention

Providers, clinic staff, patients, and community members participate in interviews to explore current barriers to referral and participation. (Year 5)

Group II: Phase II (AEP, education, interviews)Experimental Treatment4 Interventions

Participants participate in the AEP in the remaining clinics at OSUCCC/James and community clinics on study. Community members and providers participate in culturally tailored educational activities. Providers, patients, and community members participate in interviews to explore current barriers to referral and participation on study. (Years 2-4)

Group III: Phase I (interview, discussion, review, AEP, education)Experimental Treatment6 Interventions

Community members, clinic staff, and providers undergo in-depth interview for intervention development on study. Researchers review baseline data on referral patterns and accrual of racial and ethnic minorities to clinical trials in each clinic site. Providers, clinical staff, and research team participate in implementation discussion. AEP strategies developed and initiated in one OSUCCC/James clinic. Providers and community members participate in educational sessions on study. (Year 1)

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Discussion

2021

N/A

~130

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,668 Previous Clinical Trials

40,926,078 Total Patients Enrolled

1 Trials studying Blood Cancers

70 Patients Enrolled for Blood Cancers

Ohio State University Comprehensive Cancer CenterLead Sponsor

320 Previous Clinical Trials

289,959 Total Patients Enrolled

Electra D Paskett, PhDPrincipal InvestigatorOhio State University Comprehensive Cancer Center

5 Previous Clinical Trials

1,619 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the upper limit of individuals enrolled in this research endeavor?

"Affirmative. The details available on clinicaltrials.gov indicate that this particular medical study is presently seeking out participants for enrollment. Initially shared with the public on August 22nd, 2023, and most recently revised on March 13th, 2024, this trial aims to enroll a total of 208 individuals at a single site."

Answered by AI

Is the recruitment for this research study presently ongoing?

"As per clinicaltrials.gov, this research endeavor is actively seeking individuals to participate. The study was initially posted on August 22nd, 2023, and underwent its latest update on March 13th, 2024."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Outreach Project to Connect Underrepresented Populations to Clinical Trials at Ohio State University, CUSP2CT Project Trial

Electra Paskett 2023. "Outreach Project to Connect Underrepresented Populations to Clinical Trials at Ohio State University, CUSP2CT Project Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06314672.